Durable response to BRAF inhibitor monotherapy in recurrent metastatic low grade serous ovarian cancer
-
Published:2024-06
Issue:
Volume:53
Page:101412
-
ISSN:2352-5789
-
Container-title:Gynecologic Oncology Reports
-
language:en
-
Short-container-title:Gynecologic Oncology Reports
Author:
Sama ShashankORCID,
Rosqvist Sterling,
Savage Talicia,
Lomo Lesley,
Sibbald Kiera,
Straubhar Alli,
Werner Theresa L.
Reference59 articles.
1. Banerjee, S., Grochot, R., Shinde, R., Lima, J., Krebs, M.G., Rahman, R.A. et al., 2021. Phase I study of the combination of the dual RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib: results of efficacy in low grade serous ovarian cancer.
2. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766)±defactinib in recurrent low-grade serous ovarian cancer (LGSOC);Banerjee;J Clin Oncol.,2023
3. Peritoneal implants of ovarian serous borderline tumors: histologic features and prognosis;Bell;Cancer,1988
4. Dabrafenib and its use in the treatment of metastatic melanoma;Bowyer;Melanoma Manage.,2015
5. Clinicopathologic and molecular features of paired cases of metachronous ovarian serous borderline tumor and subsequent serous carcinoma;Chui;Am. J. Surg. Pathol.,2019